KG
ZVRA icon

Kilter Group’s Zevra Therapeutics ZVRA Stock Holding History

Kilter Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29K Hold
90
– – ﹤0.01% 1200
2026
Q1 		$839 Hold
90
– – ﹤0.01% 1268
2025
Q4 		$807 Hold
90
– – ﹤0.01% 1113
2025
Q3 		$856 Hold
90
– – ﹤0.01% 929
2025
Q2 		$793 Buy
+90
New +$730 ﹤0.01% 880

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kilter Group's ZVRA Position: Q2 2026 in Review

Kilter Group held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 90 shares worth $1.29K. The position accounts for ﹤0.01% of the portfolio, ranked #1200.

Kilter Group first reported a position in ZVRA in Q2 2025 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Kilter Group held 90 shares of Zevra Therapeutics worth $1.29K as of Q2 2026.
  • Kilter Group left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1200 holding.
  • Kilter Group first reported a position in Zevra Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.